These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 38856039

  • 1. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C, Beier D, Martelletti P, Pellesi L.
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [Abstract] [Full Text] [Related]

  • 2. Atogepant: an emerging treatment for migraine.
    Rustichelli C, Avallone R, Ferrari A.
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [Abstract] [Full Text] [Related]

  • 3. Gepants for the treatment of migraine.
    Negro A, Martelletti P.
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CGRP inhibitors for migraine prophylaxis: a safety review.
    Rivera-Mancilla E, Villalón CM, MaassenVanDenBrink A.
    Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
    [Abstract] [Full Text] [Related]

  • 7. Atogepant: First Approval.
    Deeks ED.
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J, Szok D, Csáti A, Vécsei L.
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T, Villalón CM, MaassenVanDenBrink A.
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [Abstract] [Full Text] [Related]

  • 13. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R, Shebley M, Trugman JM.
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel insight into atogepant mechanisms of action in migraine prevention.
    Melo-Carrillo A, Strassman AM, Broide R, Adams A, Dabruzzo B, Brin M, Burstein R.
    Brain; 2024 Aug 01; 147(8):2884-2896. PubMed ID: 38411458
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.